Episode 461: A New Disease-Modifying Therapy Has Been Submitted for FDA Approval with Dr. Jiwon Oh

A short while ago, we shared very positive results from the Phase 3 clinical trials for fenebrutinib in both relapsing-remitting and primary progressive MS. Those results have been submitted to the FDA for approval.

This week, Dr. Jiwon Oh, the principal investigator in one of the Phase 3 trials for fenebrutinib, walks us through these positive results and explains what makes fenebrutinib a different kind of disease-modifying therapy and who might benefit most from it.

We're also talking about the European approval of Cenrifki (Tolebrutinib) to treat nonrelapsing secondary progressive MS, and we'll share our perspective on why the FDA should have -- and should still -- approve this DMT in the U.S.

We'll tell you about two studies funded by the National MS Society that will focus on identifying links between menopause and MS.

We'll share some sobering news about healthcare affordability in America.

And we'll share some good news from the U.S. House Appropriations Committee, along with an opportunity for you to spend just 5 minutes doing some important advocacy work.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Fenebrutinib has been submitted to the FDA for approval  :22

Cenrifki (Tolebrutinib) approved in Europe for Nonrelapsing Secondary Progressive MS  1:09

National MS Society funds two studies to identify links between menopause and MS  4:19

Healthcare has become unaffordable for the majority of Americans  8:23

The U.S. House Appropriations Committee has approved $20 million in funding for the MS Research Program   11:57